Remove Biopharma Remove Networking Remove Specialization
article thumbnail

Enabling the next wave of innovative drug therapies with speciality enzymes

Pharmaceutical Technology

For cell and gene therapy applications, you need a variety of speciality enzymes of the highest purity, specificity, and consistency. Developing best-in-class speciality enzymes. Novozymes has a long legacy of enzyme discovery and the ability to genetically engineer these speciality enzymes to be superior.

article thumbnail

CPHI Barcelona 2023 – Event preview

European Pharmaceutical Review

Uniting the global supply chain CPHI Barcelona serves as a vital platform for unrivalled networks and access to the global supply chain. Eligible companies classified as start-ups and active in the pharma, biopharma, digital, or medical device sectors can exhibit. There has never been a better time to attend CPHI.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The Caregiver Vertical: How Pharma Engages

Pharma Marketing Network

Sunny White is an Editorial Advisory Board member for the Pharma Marketing Network with unique insights into how important caregivers are to the HCP/patient relationship and overall health outcomes. Sunny’s healthcare marketing agency, Xavier Creative House, specializes in pharmaceutical, biotech, and medical device. Sunny White.

Pharma 98
article thumbnail

Untangling the Complexities of Cell and Gene Therapy Clinical Trials: A Supply Chain Perspective 

Pharmaceutical Technology

Nearly every biopharma with a portfolio of drugs in development spanning traditional small molecules and biologics and the newer CGT operates with separate clinical supply organizations per these therapy areas. CGT have highly unique and specialized manufacturing processes.

article thumbnail

Improve Your Health, Meet in Person

PM360

The health-conscious among us pay special attention to actively managing our sleep, exercise, vitamins, etc. Biopharma should pay special attention to this. You’re the gatekeeper of all communication on your platform, and participants are unlikely to network with one another independently. The list goes on. Here’s why.

article thumbnail

Recent Trends Impacting Funding and Access to Rare Disease Therapies

PM360

Managing the complexity of commercializing rare and orphan therapies requires specialized Marketing, Medical Affairs, and Market Access teams that are up to the task. Acknowledgements: Special thanks to Sonalee Agarwal, VP, Alnylam Pharmaceuticals, and Crystal Watson, Head of HEOR, Atara Bio for their contributions to this article.

article thumbnail

Five IDNs to watch in 2023

Clarivate

healthcare provision landscape, integrated delivery networks, or IDNs, are differentiating their offerings by adding outpatient treatment centers, pursuing National Cancer Institute designations and investing in value-based care. In a fiercely competitive U.S. Christopher Silva, Senior Healthcare Research Analyst.